Stock BIO BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biotest AG Xetra

Equities

BIO

DE0005227201

Market Closed - Xetra
Other stock markets
 11:36:28 2024-04-26 am EDT 		5-day change 1st Jan Change
41.6 EUR 0.00% Intraday chart for Biotest AG 0.00% -2.35%
Apr. 19 Biotest Launches New Plasma Collection Center in Germany MT
Mar. 28 Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOTEST AG Stock Biotest AG
-2.35% 1.48B -
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
A-
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
B-
UCB Stock UCB
+57.86% 25.23B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
C
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
D+
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
B-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. BIO3 Stock
  4. BIO Stock
  5. Ratings Biotest AG